Kidney Cancer Metastatic clinical trials

Cancer vaccine made from your cells or a donor

This early-phase trial tests a whole-cell cancer vaccine for people with certain metastatic cancers. It aims to help your immune system recognize and fight the cancer, especially when prior chemotherapy hasn’t worked.

Donor NK cells with IL-15 and pembrolizumab for advanced solid tumors

This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.

Actinium-225 PSMA for advanced prostate cancer after Lu-177

This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.

OBX-115 cell therapy for advanced melanoma or lung cancer

This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.

Imaging study of new cancer-targeting radioactive drugs

This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.

Testing INV-6452 for advanced breast cancer and solid tumors

This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.

Removing the main kidney tumor during immunotherapy for advanced kidney cancer

This trial tests whether removing or burning (ablating) the main kidney tumor helps people with advanced kidney cancer who are already doing well on immunotherapy. Researchers want to see if combining local treatment with ongoing immunotherapy can improve outcomes.

PSMA-targeted radioactive drug for advanced prostate cancer

This Phase 1/2 study tests a radioactive treatment that targets PSMA, a protein often found on prostate cancer cells. It’s for men whose prostate cancer has worsened despite hormone-blocking pills like abiraterone or enzalutamide, aiming to help shrink or control the disease.

Immune therapy for HR-positive, HER2-negative metastatic breast cancer

This Phase 2 trial studies an immune-based treatment for women with HR-positive and HER2-negative breast cancer that has spread or returned and can’t be cured with local treatment alone. The goal is to see whether the therapy can shrink tumors and improve disease control with acceptable safety.

Turn unresectable liver cancer into operable colorectal cancer

This Phase 2 study tests a treatment strategy to shrink or control colorectal cancer that has spread only to the liver, with the goal of making it removable by surgery. If you qualify, it may offer a chance to move from “not operable” to “operable,” but it’s still experimental.

Fulvestrant or capecitabine after chemo for metastatic breast cancer

This Phase 3 trial compares two medicines—fulvestrant versus capecitabine—as “maintenance” treatment after your first chemo helps control metastatic breast cancer. It aims to see which one helps people live longer with better disease control.

Testing a new cancer drug plus capecitabine for metastatic colon cancer

This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.

Paclitaxel micelles for metastatic breast cancer

This trial tests a new form of paclitaxel (a chemotherapy drug) for metastatic breast cancer that is HER2-negative. It may be an option if your cancer has returned or not improved after 2 to 4 previous treatments.

Second-line treatment for advanced colorectal cancer

This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.

Local liver treatment for colorectal cancer that has spread

This trial tests whether treating liver tumors with surgery or ablation can help people whose colorectal cancer has spread to the liver and other organs. It may be an option if you've had only 1 or 2 types of chemotherapy and your non-liver metastases are stable.

Testing different drug combos for HER2-positive breast cancer

This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.

Glumetinib and Fruquintinib for advanced colorectal cancer

This trial tests a combination of two targeted drugs (Glumetinib and Fruquintinib) for people with a specific type of advanced colorectal cancer that has a change in the MET gene (amplification) or too much MET protein. It is for those whose cancer has not responded to at least two prior treatments.

New imaging tracer for metastatic prostate cancer

This trial tests a new radioactive tracer that may help doctors see and treat prostate cancer that has spread. The tracer attaches to cancer cells so they show up on scans, and may also help guide treatment.

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Genetic test to match treatment for advanced kidney cancer

This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.

SYN818 for advanced solid tumors with DNA repair defects

This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).

Capacitabine with or without elacestrant for ER+ breast cancer

This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.

Radioactive treatment for advanced kidney cancer

This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.

Digital symptom tracking for kidney cancer treatment

This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.